Inventage Lab, a company specializing in long-term injectables and lipid nanoparticle (LNP) research and development, is reportedly close to finalizing a technology transfer agreement with a prominent South Korean pharmaceutical company, boasting annual sales exceeding $769 million. The potential agreement focuses on 'IVL3021 (developmental code name),' a one-month long-term injectable formulation of Semaglutide designed for diabetes and obesity treatments.

Sources within the investment industry revealed on January 1st that negotiations between Inventage Lab and the pharmaceutical giant regarding the technology transfer deal for IVL3021 have made significant headway. Industry observations suggest the contract could be concluded as early as this week. However, the precise timing of the deal's finalization remains unconfirmed.

A senior executive in the bio industry noted that since their Investor Relations (IR) activity in August, Inventage Lab has been actively pursuing pipeline deals with major South Korean pharmaceutical companies. There's strong anticipation surrounding the possibility of sealing a technology transfer deal for IVL3021 with a Korean pharmaceutical company early in the current year.

Inventage Lab is advancing the development of a one-month long-term prescription leveraging its proprietary 'IVL-DrugFluidic' technology. With a focus on enhancing convenience and achieving precise control over drug release in long-acting injectables, the company aims to establish IVL3021's distinguishing quality. This year's objectives include validating the non-clinical efficacy and toxicity evaluations of IVL3021, aiming for a swift entry into clinical trials.

Semaglutide, a GLP-1 (Glucagon-like peptide-1) receptor agonist, originates from Danish pharmaceutical company Novo Nordisk. It has demonstrated remarkable efficacy, enabling more than 15% weight loss, and clinical findings suggest a 20% reduction in the risks associated with heart failure, stroke, and cardiovascular death.

In October 2022, Inventage Lab inked a joint development and commercialization pact with Yuhan Care, a subsidiary of Yuhan Corporation, focusing on long-acting injectables utilizing potential medical cannabis candidates. Multiple major Korean pharmaceutical companies, including Yuhan Corporation and others engaged in obesity treatments, have exhibited substantial interest in Inventage Lab's long-acting injectables.